Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease

Abstract

Alexander disease is a rare disorder of the central nervous system of unknown etiology1,2. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures and psychomotor retardation, leading to death usually within the first decade; patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course. The pathological hallmark of all forms of Alexander disease is the presence of Rosenthal fibers, cytoplasmic inclusions in astrocytes that contain the intermediate filament protein GFAP in association with small heat-shock proteins3,4. We previously found that overexpression of human GFAP in astrocytes of transgenic mice is fatal and accompanied by the presence of inclusion bodies indistinguishable from human Rosenthal fibers5. These results suggested that a primary alteration in GFAP may be responsible for Alexander disease. Sequence analysis of DNA samples from patients representing different Alexander disease phenotypes revealed that most cases are associated with non-conservative mutations in the coding region of GFAP. Alexander disease therefore represents the first example of a primary genetic disorder of astrocytes, one of the major cell types in the vertebrate CNS.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: GFAP mutations in Alexander disease patients characterized by DNA sequencing.
Figure 2: Detection of mutations by restriction endonuclease digestion.
Figure 3: Location of mutations in GFAP associated with Alexander disease in relation to protein domain structure of intermediate filaments.

References

  1. 1

    Duckett, S. & Goldman, J.E. in Pediatric Neuropathology (ed. Duckett, S.) 620–624 (Williams & Wilkins, Baltimore, 1995).

  2. 2

    Johnson, A.B. in Handbook of Clinical Neurology: Neurodystrophies and Neurolipidoses (ed. Moser, H.G.) 701–710 (Elsevier, Amsterdam, 1996).

  3. 3

    Johnson, A.B. & Bettica, A. On-grid immunogold labeling of glial intermediate filaments in epoxy-embedded tissue. Am. J. Anat. 185, 335–341 (1989).

  4. 4

    Iwaki, T., Kume-Iwaki, A., Liem, R.K.H. & Goldman, J.E. αB-Crystallin is expressed in non-lenticular tissues and accumulates in Alexander's disease brain. Cell 57, 71 –78 (1989).

  5. 5

    Messing, A. et al. Fatal encephalopathy with astrocyte inclusions in GFAP transgenic mice. Am. J. Pathol. 152, 391– 398 (1998).

  6. 6

    Leegwater, P.A. et al. The gene for leukoencephalopathy with vanishing white matter is located on chromosome 3q27. Am. J. Hum. Genet. 65 , 728–734 (1999).

  7. 7

    Coffeen, C.M. et al. Genetic localization of an autosomal dominant leukodystrophy mimicking chronic progressive multiple sclerosis to chromosome 5q31. Hum. Mol. Genet. 9, 787–793 (2000).

  8. 8

    Brenner, M. et al. Characterization of human cDNA and genomic clones for glial fibrillary acidic protein. Mol. Brain Res. 7, 277–286 (1990).

  9. 9

    Besnard, F. et al. Multiple interacting sites regulate astrocyte-specific transcription of the human gene for glial fibrillary acidic protein. J. Biol. Chem. 266, 18877–18883 ( 1991).

  10. 10

    Cooper, D.N. & Youssoufian, H. The CpG dinucleotide and human genetic disease. Hum. Genet. 78, 151– 155 (1988).

  11. 11

    Fuchs, E. The cytoskeleton and disease: genetic disorders of intermediate filaments . Annu. Rev. Genet. 30, 197– 231 (1996).

  12. 12

    Goldfarb, L.G. et al. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nature Genet. 19, 402–403 (1998).

  13. 13

    Sjôberg, G. et al. A missense mutation in the desmin rod domain is associated with autosomal dominant distal myopathy, and exerts a dominant negative effect on filament formation. Hum. Mol. Genet. 8, 2191–2198 (1999).

  14. 14

    Bonne, G. et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nature Genet. 21 , 285–288 (1999).

  15. 15

    Coulombe, P.A. et al. Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: genetic and functional analyses. Cell 66, 1301–1311 ( 1991).

  16. 16

    Irvine, A.D. & McLean, W.H.I. Human keratin diseases: the increasing spectrum of disease and subtlety of the phenotype-genotype correlation. Br. J. Dermatol. 140, 815–828 (1999).

  17. 17

    Gomi, H. et al. Mice devoid of the glial fibrillary acidic protein develop normally and are susceptible to scrapie prions. Neuron 14, 29–41 (1995).

  18. 18

    Pekny, M. et al. Mice lacking glial fibrillary acidic protein display astrocytes devoid of intermediate filaments but develop and reproduce normally. EMBO J. 14, 1590–1598 ( 1995).

  19. 19

    McCall, M.A. et al. Targeted deletion in astrocyte intermediate filament ( Gfap ) alters neuronal physiology. Proc. Natl. Acad. Sci. USA 93, 6361–6366 ( 1996).

  20. 20

    Liedtke, W., Edelmann, W., Chiu, F.-C., Kucherlapati, R. & Raine, C.S. Experimental autoimmune encephalomyelitis in mice lacking glial fibrillary acidic protein is characterized by a more severe clinical course and an infiltrative central nervous system lesion. Am. J. Pathol. 152, 251–259 (1998).

  21. 21

    Howard, R.S. et al. A familial disorder associated with palatal myoclonus, other brainstem signs, tetraparesis, ataxia and Rosenthal fibre formation. J. Neurol. Neurosurg. Psychiatry 56, 977– 981 (1993).

  22. 22

    Schwankhaus, J.D., Parisi, J.E., Gulledge, W.R., Chin, L. & Currier, R.D. Hereditary adult-onset Alexander's disease with palatal myoclonus, spastic paraparesis, and cerebellar ataxia . Neurology 45, 2266–2271 (1995).

  23. 23

    Rosenthal, W. Über eine eigenthümliche, mit syringomyelie complicirte geschwulst des rückenmarks. Bietr. Pathol. Anat. 23, 111–143 (1898).

  24. 24

    Herndon, R.M., Rubinstein, L.J., Freeman, J.M. & Mathieson, G. Light and electron microscopic observations on Rosenthal fibers in Alexander's disease and in multiple sclerosis. J. Neuropathol. Exp. Neurol. 29, 524–551 ( 1970).

  25. 25

    Schuelke, M. et al. Mutant NDUFV1 subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy. Nature Genet. 21, 260–261 (1999).

  26. 26

    Iwaki, A. et al. Accumulation of α B-crystallin in brains of patients with Alexander's disease is not due to an abnormality of the 5′-flanking and coding sequence of the genomic DNA. Neurosci. Lett. 140, 89–92 (1992).

  27. 27

    Klein, E.A. & Anzil, A.P. Prominent white matter cavitation in an infant with Alexander's disease. Clin. Neuropathol. 13, 31–38 (1994).

  28. 28

    Reichard, E.A.P., Ball, W.S. & Bove, K.E. Alexander disease—a case report and review of the literature. Pediatr. Pathol. Lab. Med. 16, 327–343 (1996).

  29. 29

    Brenner, M., Kisseberth, W.C., Su, Y., Besnard, F. & Messing, A. GFAP promoter directs astrocyte-specific expression in transgenic mice. J. Neurosci. 14, 1030 –1037 (1994).

  30. 30

    Isaacs, A., Baker, M. & Hutton, M. Determination of the gene structure of human GFAP and absence of coding region mutations associated with frontotemporal dementia with Parkinsonism linked to chromosome 17. Genomics 51, 152–154 (1998).

Download references

Acknowledgements

We thank the Brain and Tissue Bank for Developmental Disorders at the University of Maryland (supported by NIH), the National Neurological Specimen Bank, and the Laboratorio di Diagnosi Pre e Postnatale delle Malattie Metaboliche (Instituto G. Gaslini; supported by Telethon project C.20) for samples of Alexander disease tissues from their collections; A. Koeppen and M. Mahadevan for control samples; the AECOM Human Genetics Program and J. Cowell for helping to prepare some of the samples; D. Klimanis, J. Salmon and Y. Yang for processing samples and data analysis; J. Nagle and S. Hollingshead for sequencing; L. Harman for paternity testing; R. Spritz and M. Hutton for advice; the families of Alexander disease patients for encouragement and assistance; and the United Leukodystrophy Foundation for support. The UAB sequencing facility is partially supported by grants from the Tennessee Valley Authority and the Howard Hughes Foundation. During the early stages of this work, M.B. was supported at the NIH by the NINDS intramural program through J.M. Hallenbeck. This project was supported by NIH grants NS-22475 (A.M.) and EY-09331 (J.E.G.), by the Lie Endowment (M.B.), and by the Institut National de la Santé et de la Recherche Médicale, the European Leukodystrophies Association (ELA France), the Biomed 2 EC project and the Jean Pierre and Nancy Boespflug Foundation for Myopathic Research (O.B.-T. and D.R.).

Author information

Correspondence to Albee Messing.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Brenner, M., Johnson, A., Boespflug-Tanguy, O. et al. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 27, 117–120 (2001) doi:10.1038/83679

Download citation

Further reading